Skip to content
drillr.ai
Sign up

ALXO

ALX Oncology Holdings Inc.

NASDAQ · Healthcare · Biotechnology · US

$2.01
−0.99%
Ask drillr

  • Aug 6, 2026, 12:00 UTC

    ALX Oncology announced the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel.

    Source:

  • Aug 6, 2026, 00:00 UTC

    ALX Oncology Holdings refinanced $10 million of existing debt and obtained an additional $20 million under a new $50 million loan facility, with $10 million uncommitted.

  • Aug 6, 2026, 00:00 UTC

    ALX Oncology Holdings reported a Q2 2026 net loss of $17.97 million, or $0.13 per diluted share, with cash and investments of $153.4 million as of June 30, 2026.

  • Jun 26, 2026, 00:00 UTC

    ALX Oncology Holdings Inc. entered into a secured multi-tranche term loan facility with HSBC Ventures USA Inc., drawing $10 million at closing to refinance existing debt and pay closing costs, with additional tranches available through June 30, 2028, maturing June 1, 2030.